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ABSTRACT
Objective To evaluate the influence of the
mitochondrial DNA (mtDNA) haplogroups in the risk of
incident knee osteoarthritis (OA) and to explain the
functional consequences of this association to identify
potential diagnostic biomarkers and therapeutic targets.
Methods Two prospective cohorts contributed
participants. The osteoarthritis initiative (OAI) included
2579 subjects of the incidence subcohort, and the
cohort hip and cohort knee (CHECK) included 635, both
with 8-year follow-up. The analysis included the
association of mtDNA haplogroups with the rate of
incident knee OA in subjects from both cohorts followed
by a subsequent meta-analysis. Transmitochondrial
cybrids harbouring haplogroup J or H were constructed
to detect differences between them in relation to
physiological features including specific mitochondrial
metabolic parameters, reactive oxygen species
production, oxidative stress and apoptosis.
Results Compared with H, the haplogroup J associates
with decreased risk of incident knee OA in subjects from
OAI (HR=0.680; 95% CI 0.470 to 0.968; p<0.05) and
CHECK (HR=0.728; 95% CI 0.469 to 0.998; p<0.05).
The subsequent meta-analysis including 3214 cases
showed that the haplogroup J associates with a lower
risk of incident knee OA (HR=0.702; 95% CI 0.541 to
0.912; p=0.008). J cybrids show a lower free radical
production, higher cell survival under oxidative stress
conditions, lower grade of apoptosis as well as lower
expression of the mitochondrially related pro-apoptotic
gene BCL2 binding component 3 (BBC3). In addition,
J cybrids also show a lower mitochondrial respiration
and glycolysis leading to decreased ATP production.
Conclusions The physiological effects of the
haplogroup J are beneficial to have a lower rate of
incident knee OA over time. Potential drugs to treat OA
could focus on emulating the mitochondrial behaviour of
this haplogroup.
INTRODUCTION
Osteoarthritis (OA) is a chronic progressive dis-
order involving movable joints characterised by cell
stress and extracellular matrix degradation initiated
by micro-injury and macro-injury that activates mal-
adaptive repair responses including pro-inflammatory
pathways of innate immunity. The disease manifests
first as a molecular derangement (abnormal tissue
metabolism) followed by anatomical and/or physio-
logical derangements (characterised by cartilage
degradation, bone remodelling, osteophyte forma-
tion, joint inflammation and loss of normal joint
function) that can culminate in illness.1
OA is the most common form of arthritis, occur-
ring in 10%–20% of the population aged over
50 years, and it is estimated that the population
with OA will double in the next 30 years.2 Thus,
the identification of risk factors that accelerate
disease progression is critical since these factors
could become potential targets for disease modifi-
cation.3 To achieve this objective, the use of well-
characterised study cohorts to identify prognostic
factors that predict the course of OA, as well as
to identify markers for the (early) diagnosis and
course of joint damage, becomes imperative. In this
sense, both osteoarthritis initiative (OAI) and
cohort hip and cohort knee (CHECK) stand out.
OA is a heterogeneous disease in which a com-
bination of modifiable (ie, body mass index (BMI),
joint injury) and non-modifiable factors (ie, age,
gender, genetics) interact. Thus, the pathogenesis
of OA is still unclear; however, it is widely accepted
that genetics plays a main role in the prevalence
and progression of this disease;4 even prediction
tools for knee OA based on genetic and clinical
information have been developed.5 6 Besides,
during the last years, increasing evidence points to
the implication of the mitochondria and the mito-
chondrial DNA (mtDNA) haplogroups in the
pathogenesis of the disease.2 7 8
The mtDNA haplogroups are the result of mater-
nally inherited mutations in the mtDNA acquired
throughout the human history and shaped by the
climate selection when humans migrated into
colder climates.9 10 Each of the mtDNA hap-
logroups harbours specific single nucleotide poly-
morphisms (SNPs) that influence the behaviour of
the mitochondria11 and interact with the nuclear
genome,12 influencing our health today.10 Some of
these genetic variants have been associated with
degenerative disorders,13 metabolic alterations14 or
even increased longevity in humans.15
Regarding OA, several studies also reported the
association of specific haplogroups with a lower
prevalence of the disease,16–19 while others did
not.20 Moreover, recent studies showed significant
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associations of specific haplogroups with a lower rate of radio-
graphic progression and cartilage loss over time in different study
cohorts worldwide such as the OAI21 and one Spanish cohort.22
In an attempt to ascertain the correlation of mtDNA hap-
logroups and the rate of incident knee OA, in this work we per-
formed a replication study and meta-analysis of two individual
studies involving subjects from CHECK and OAI cohorts. In
addition, functional studies using transmitochondrial cybrids
were performed to ascertain the cellular mechanisms underlying
the association of mtDNA variants with the pathogenesis of the
disease.
METHODS
Incident knee OA study in subjects from the OAI and CHECK
cohorts
Participants
The description of CHECK and OAI cohorts is included in the
online supplementary methods section. For this study, we
included longitudinal data, in terms of Kellgren and Lawrence
(KL) grade, of 2579 participants of the incidence subcohort of
the OAI and 635 CHECK participants that met the eligibility
criteria for an incident knee OA study monitored at predefined
intervals for a period of 8 years.
Incident knee OA criteria
The incidence of radiographic knee OA was defined on joint
level (knees separately) following the appropriate proposed cri-
teria for each of the two cohorts. In OAI subjects, we followed
the definition of incident knee OA proposed by Felson et al23
consisted in a new-onset KL grade ≥2 from baseline to
follow-up. In CHECK subjects, we followed the proposed defin-
ition of incident knee OA for this cohort24 25 consisted in a
new-onset KL grade ≥1 from baseline to follow-up in accord-
ance with the very early stage OA in CHECK subjects.
mtDNA haplogroups genotyping
The mtDNA haplogroups were assigned in 2579 DNA samples
belonging to the OAI and 635 from CHECK following a previ-
ously described assay16 (see online supplementary methods).
Statistical analysis
All the statistical analyses were performed using IBM-SPSS soft-
ware V.19 (IBM, Armonk, New York, USA) and R software
V.3.1.2 (The R Foundation for Statistical Computing). All com-
parisons were two-sided, with p<0.05 defined as statistically
significant.
To avoid potential biases associated with the use of standard
survival analysis in this context, interval-censored data analysis
methods were used (see supplementary methods section). The
multivariate analysis was performed by comparisons between
haplogroups considering the most common haplogroup H as
the reference group. Since there was no interest in all possible
pairwise comparisons, no additional adjusting for multiple com-
parisons was done.
Meta-analysis
In this work, we performed a meta-analysis of incident knee OA
including data from CHECK and OAI. Following the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines, we conducted a previous computerised
search strategy to find other possible relevant studies to include
in the meta-analysis (see supplementary methods).
The random-effects model described by DerSimonian and
Laird26 was used to calculate a summary statistic and its 95%
CI. Adjusted HRs were used as the effect size measure for the
association between mtDNA haplogroups and OA incidence.
Meta-analysis results were presented on a forest plot graph. To
explore heterogeneity, the I2 index was computed. Meta-analysis
was carried out using the R software programme (V.3.2.2), using
the meta-package. A two-tailed p value <0.05 was considered
to be significant. Meta-analysis was planned to be performed on
k=2 studies, with an estimated statistical power of 91.9% to
detect as statistically significant an HR ≤0.5 associated with
each haplogroup, with a p=0.05 two-tailed significance level.
We only selected studies that met the following inclusion cri-
teria: (i) evaluating the association between mtDNA hap-
logroups and the rate of incident OA over time; (ii) with
sufficient data provided to calculate HRs with their correspond-
ing 95% CI. On the contrary, those studies analysing the correl-
ation between mtDNA haplogroups and the prevalence or risk
of OA as well as those studies analysing other mtDNA muta-
tions with incidence were excluded.
Functional studies using transmitochondrial cybrids
An extended version of the methodology described herein is
available in the online supplementary methods.
Cybrid cultures and culture conditions
The human osteosarcoma cell line 143B.TK− Rho-0 was used to
generate the transmitochondrial cybrids by fusing them with
platelets from healthy donors carrying the haplogroups J or H
following the protocol described by Chomyn,27 such that we
finally obtained two types of cybrids: cybrids harbouring hap-
logroup J and cybrids harbouring haplogroup H.
Flux assay measurements
Extracellular acidification rate (ECAR) (largely result of glycoly-
sis) and oxygen consumption rate (OCR) (indicator of mito-
chondrial respiration) was determined by direct measurement in
a SeaHorse XFp extracellular flux analyser instrument (Seahorse
Bioscience, Agilent Technologies) following manufacturer’s
instructions.
Mitochondrial reactive oxygen species production assay
Mitochondrial peroxide and peroxynitrite were evaluated with
dihydrorhodamine 123 (Sigma) and mitochondrial superoxide
anion production was assessed with MitoSox Red (Thermo
Fisher Scientific).
Oxidative stress response assay: viability assay
After incubation of cells with 300 mMH2O2, the cell viability
was measured using CellTiter 96 Aqueous Assay (Promega) fol-
lowing manufacturer’s recommendations.
Apoptosis assay
Cells were cultured in presence of staurosporine at 0.2 mM
during 2 hours to induce apoptosis and were subsequently
washed and resuspended in 1X Annexin-binding buffer; then
5 μL of the Annexin V-fluorescein isothiocyanate and 5 μL of
propidium iodide (ImmunoStep) were added to each 100 μL of
cell suspension.
In addition, the basal expression of the mitochondrial
apoptotic-related genes B-cell CLL/lymphoma 2-like 13
(BCL2L13) and BCL2 binding component 3 (BBC3) in H and J
cybrids was also quantified.
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Results were expressed as the mean of three independent experi-
ments (mean±SD) using two cybrids (two J cybrids and two H
cybrids) from two individuals (two different J individuals and
two different H individuals) and two clones from each cybrid.
Statistically significant differences between the two groups were
determined with t-test; p values <0.05 were considered to be
significant.
RESULTS
mtDNA haplogroups and incident knee OA in subjects of the
OAI cohort
No significant differences were detected in the distribution of
age, BMI, Western Ontario and McMaster Universities Arthritis
Index (WOMAC) and contralateral OA at baseline among
patients with different haplogroups; however, a significantly dif-
ferent gender distribution was identified, both being hap-
logroups H and J that showed an increased percentage of
females than the rest of haplogroups (table 1).
Cumulative probability of incident knee OA at 8 years was
25.1%. Subjects with the haplogroup J showed the lowest rate
of incident knee OA over time, 20.1% (adjusted HR=0.680;
95% CI 0.470 to 0.968; p<0.05). In addition, males had a
decreased risk too (adjusted HR=0.590; 95% CI 0.491 to
0.712; p<0.05), meanwhile BMI (adjusted HR=1.066; 95% CI
1.047 to 1.085; p<0.05), total WOMAC (adjusted HR=1.018;
95% CI 1.010 to 1.026;p<0.05) and contralateral knee OA
(adjusted HR=1.593; 95% CI 1.328 to 1.900; p<0.05) at
baseline were risk factors for a higher risk of incident knee
OA (table 2).
mtDNA haplogroups and incident knee OA in subjects of
CHECK cohort
No significant differences were detected in the distribution of
age, gender, BMI, WOMAC and contralateral OA at baseline
among patients with different haplogroups (table 1).
Global cumulative probability of incident knee OA at 8 years
was 89.7%. The cumulative knee OA incidence was significantly
lower in carriers of the haplogroup J, with 82.1% (adjusted
HR=0.728; 95% CI 0.469 to 0.998; p<0.05). In addition, the
model also showed that total WOMAC (adjusted HR=1.006;
95% CI 1.001 to 1.012; p<0.05) and contralateral knee OA
(adjusted HR=1.313; 95% CI 1.087 to 1.576; p<0.05) at base-
line were risk factors to develop incident knee OA (table 2).
Meta-analysis
The search process identified a total of seven non-duplicated
articles and no unpublished article16 18 22 28–31 (see online
supplementary table S1). However, after reading the titles and
abstracts none of these seven articles was subsequently selected
for meta-analysis because they did not follow the inclusion cri-
teria; namely, they did not evaluate the association between
mtDNA haplogroups and the rate of incident knee OA over
time but analysed the association between these mtDNA var-
iants, or any other mtDNA mutations, and the prevalence of
OA in cross-sectional studies. In conclusion, only the two associ-
ation studies performed herein were selected for subsequent
meta-analysis reaching a total of 3214 subjects (2579 patients
from the OAI and 635 patients from CHECK) (table 3).
No between-study heterogeneity was detected for the hap-
logroup J (I2=0%; p=0.798), however, the random-effects
model was evenly used. Both studies showed a similar contribu-
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study (52.2%) compared with CHECK (47.8%). The results
showed that haplogroup J significantly reduces the risk of inci-
dent knee OA (combined HR=0.702; 95% CI 0.541 to 0.912;
p=0.008) (figure 1).
Functional study using transmitochondrial cybrids
Establishment of basal conditions
At 25 passages, the mtDNA copy number between H and J
cybrids acquired the steady state levels (data not shown), mean-
while at 48 hours the doubling time (DT) showed no significant
differences between H and J cybrids (data not shown). Based on
these setting, all the experiments were performed starting from
25 passages and after 48 hours of cell culture.
Mitochondrial respiration and glycolytic capacity
To measure real-time glycolytic and mitochondrial respiration
rates, cybrids were placed in an extracellular flux analyser
(Seahorse Biosciences). The analyser measures ECAR and OCR
in a transient microchamber, representing glycolysis and mito-
chondrial respiration, respectively. Glycolysis rate in H and J
cybrids were 87.98±11.4 and 69.45±4.69 mpH/min, respec-
tively, indicating a 21.06% decrease in J cybrids (p=0.0004);
Table 2 Cumulative probability of incident knee OA at 8 years in subjects from the OAI and CHECK cohorts according to mtDNA haplogroups
and results of the extended Cox proportional hazard model
Variables
Cumulative knee OA incidence at 8 years
n (%)* Adjusted HR 95% CI†
OAI
Gender (male) 0.590 0.491 to 0.712‡
Age 1.007 0.997 to 1.017
BMI 1.066 1.047 to 1.085‡
WOMAC (total) 1.018 1.010 to 1.026‡
Contralateral OA at baseline 1.593 1.328 to 1.900‡
mtDNA haplogroups (N=2579)
H (n=1042) 278 (26.7%) 1
UK (n=612) 154 (25.1%) 0.908 0.727 to 1.131
T (n=275) 67 (24.3%) 0.896 0.658 to 1.221
J (n=236) 47 (20.1%) 0.680 0.470 to 0.968‡
Others§ (n=414) 102 (24.6%) 0.895 0.698 to 1.153
CHECK
Gender (male) 0.869 0.698 to 1.043
Age 1.007 0.990 to 1.026
BMI 1.005 0.987 to 1.025
WOMAC (total) 1.006 1.001 to 1.012‡
Contralateral OA at baseline 1.313 1.087 to 1.576‡
mtDNA haplogroups (N=635)
H (n=269) 248 (92.2%) 1
UK (n=144) 126 (87.5%) 0.849 0.682 to 1.035
T (n=68) 64 (94.1%) 1.133 0.850 to 1.447
J (n=56) 46 (82.1%) 0.728 0.469 to 0.998‡
Others§ (n=98) 86 (87.7%) 0.810 0.627 to 1.032
*Cumulative incident knee OA rate from baseline to follow-up.
†CIs for the HRs obtained using the bootstrap methodology by the improved percentile method.
‡Statistical significance declared at p≤0.05.
§The group ‘others’ include mtDNA variants with a frequency below 5%.
Bold refers to parameters that reached the statistical significance (p≤0.05).
BMI, body mass index; CHECK, cohort hip and cohort knee; mtDNA, mitochondrial DNA; OA, osteoarthritis; OAI, osteoarthritis initiative, WOMAC, Western Ontario and McMaster
Universities Arthritis Index.
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glycolytic capacity rates in H and J cybrids were 116.3±12.76
and 91.69±6.48 mph/min, respectively, indicating a 21.16%
decrease in J cybrids (p<0.0001) (figure 2A). Similarly, mito-
chondrial basal respiration rate was significantly lower in J
cybrids (96.58±60.01 pmol/min) compared with H cybrids
(209.08±55.7 pmol/min, p=0.007); as a result, H cybrids
showed an increased ATP production (149.95±23.29 vs 65.94
±25.72 pmol/min in J cybrids; p<0.0001) (figure 2B).
Mitochondrial reactive oxygen species production and oxidative
stress response
Cybrids carrying the haplogroup H had a significantly higher
production of peroxide and peroxynitrite than cybrids carrying
the haplogroup J (52.51±11.34 vs 41.26±7.48; p<0.05)
(figure 2C). Moreover, the analysis of mitochondrial anion
superoxide revealed the same significant trend by which H
cybrids showed higher levels than J cybrids (8.58±3.0 vs 4.25
±0.9; p<0.05) (figure 2D).
In relation to oxidative stress response, the results showed
that the percentage of survival cells in presence of H2O2 in H
cybrids was significantly lower than in J cybrids (29.63±3.3 vs
56.45±7.36; p<0.05) (figure 2E).
Analysis of apoptosis
The analysis of apoptosis assessed in basal conditions revealed
no significant differences between H and J cybrids (3.69±2 and
4.17±1.1, respectively; p>0.05) (data not shown). However,
after incubation with staurosporine, cybrids carrying the hap-
logroup H showed a significantly increased number of apoptotic
cells in comparison with J cybrids (7.35±3.78 vs 4.69±1.68;
p<0.05) (figure 2F).
Further analysis of the pro-apoptotic gene BBC3 and the anti-
apoptotic gene BCL2L13 showed a significantly increased
expression of BBC3 in H cybrids compared with J cybrids
(3.3-fold; p<0.05). On the contrary, no significant differences
were detected in the expression of BCL2L13 (figure 2G).
DISCUSSION
Here, we report the first replication study followed by a
meta-analysis addressing the association between mtDNA hap-
logroups and the risk of incident knee OA over time using new
haplogroup data from two well-characterised cohorts of
patients; a previous meta-analysis involving the study of the
mtDNA haplogroups consisted in the analysis of their associ-
ation with the prevalence of the disease.28 In addition, we
provide data supporting the possible explanation for these asso-
ciations using transmitochondrial cybrids.
We assessed, for the first time, the influence of the mtDNA
haplogroups in the rate of incident knee OA in subjects of the
incidence subcohort of the OAI followed by a replication study
in patients from CHECK. Despite OAI and CHECK are geo-
graphically different cohorts, the frequency distribution of
the mtDNA haplogroups was very similar between both cohorts
(χ2 test; p=0.924, data not shown), ruling out a potential
confusion due to ethnic origin. Compared with the incidence
subgroup of the OAI, CHECK participants experienced an
increased radiographic change at follow-up (89.7% vs 25.1%)
mainly because of the different incident knee OA criteria and
mean age at baseline between both cohorts, as previously
described.32 Although both cohorts focus on the early phase of
OA, the CHECK cohort represents participants in an even
earlier state of the disease33 and the incident knee OA criteria
slightly differs from the proposed by Felson et al23 in subjects
of the OAI. Notwithstanding, the results obtained reveal that
subjects with haplogroup J show a lower rate of incident knee
OA in both cohorts.
To date, different associations involving the haplogroup J
have been described in the context of OA. Subjects carrying this
haplogroup have a lower prevalence of knee and/or hip
OA,16 17 19 28 besides this mtDNA variant also associates with
lower serum levels of catabolic type II collagen biomarkers34
and metalloproteinases (MMPs)35 and has been correlated with
higher telomere length and lower nitric oxide production in
articular chondrocytes.36 However, a work by Hudson et al
found no evidence of associations between mtDNA variants and
the risk of OA.20 Although the study by Hudson et al is a preva-
lence study, and not an incident knee OA analysis as is the case
of the study presented herein, some points could clarify this;
control samples used in their study are population-based con-
trols with symptomatic information and without radiographic
data. Up to 50% of patients without joint symptoms may have
radiographic changes related to OA,37 therefore, the selection of
adequate healthy controls is crucial to draw consistent conclu-
sions in case-control studies; this point could be one of the
causes by which one study performed by the arcOGEN consor-
tium also failed to replicate previous associations at genome-
wide significance level (p≤5.0×10−8), such as GDF5, chromo-
some 7q22 or MCF2L gene polymorphisms.38 Finally, as postu-
lated by these authors, the relative contribution of specific
mtDNA variants could vary in different ethnic groups by means
of homoplasy and/or geographic differences in the finer details
of subhaplogroup structures of mtDNA.20
The results of the meta-analysis indicate that the associations
are robust and reveal a strong association with the haplogroup
J. The haplogroup J is characterised by a set of uncoupling
Figure 1 Forest plot of the associations analysed separately in this work involving the mitochondrial DNA haplogroup J and the risk of incident
knee OA. OA, osteoarthritis; OAI, osteoarthritis initiative; CHECK, cohort hip and cohort knee; W, relative weight; Haplo. J, number of subjects with
the haplogroup J that developed and did not develop incident knee OA during the follow-up; p Val: p Value.
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Figure 2 (A) Glycolysis stress test by extracellular acidification rate (ECAR) traces and bar graphs showing the glycolytic response of H and J
cybrids in response to glucose, oligomycin (oligo) and 2-deoxy-glucose (2-DG) injection where indicated. Bar graphs show glycolysis and glycolytic
capacity as calculated from trace and compared between groups. (B) Mitochondrial stress test by OCR traces and bar graphs showing the
mitochondrial behaviour in H and J cybrids in response to oligomycin, FCCP and rotenone/antimycin (Rot/AntA) injection where indicated. Bar
graphs show basal respiration and ATP production, calculated and compared between groups; (C) mitochondrial peroxide and peroxynitrite
production; (D) mitochondrial anion superoxide production; (E) susceptibility to oxidative stress after incubation with 300 mM H2O2; (F) apoptosis
measure with Annexin-V-fluorescein isothiocyanate: data are expressed as percentage of positive cells under stress induction with staurosporine at
0.2 mM; (G) gene expression of the apoptotic genes BBC3 and BCL2. The values represented were a mean±SD of three independent experiments
using two cybrids from two different individuals and two clones from each cybrid. Black bars corresponds to H cybrids, while grey bars correspond
to J cybrids; BBC3, BCL2 binding component; FCCP, carbonyl cyanide p-trifluoromethoxyphenylhydrazone; ***p<0.0001; **p<0.01; *p<0.05.
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mitochondrial polymorphisms,9 10 preferentially non-synonymous
SNPs,39 acquired during its evolutionary history. These aspects
make this haplogroup to be biochemically different from other
mitochondrial variants, specially the haplogroup H.40 41
Increasing evidence suggests that low-grade chronic inflamma-
tion in the joint promotes OA progression, and changes in cellu-
lar bioenergy metabolism can reprogramme inflammatory
response, leading to the disturbance of cellular energy balance
and increase cell stress.42 This evidence implies that mitochon-
dria, as the regulators of cell metabolism, as well as the mtDNA
haplogroups, as one of the main modulators of cellular bioener-
getics,43 are involved in the development of OA as previously
proposed.2 44 Nevertheless, in an attempt to find out the pos-
sible cellular mechanisms underlying the associations described
herein, we performed a functional study of the mtDNA
haplogroups using transmitochondrial cybrids.
Transmitochondrial cybrids are cell lines consisting of mito-
chondria from different sources in a defined and uniform
nuclear background. They constitute an interesting model and
allow the study of the real role of different mtDNA polymorph-
isms under identical nuclei, and they also provide a window
into early stages of disease pathogenesis, which is not available
from pathological specimens. Because of that, these cell
models have been proposed and widely used to explore the con-
tribution of mitochondrial dysfunction and mtDNA mutations
to the pathogenesis of human diseases, such as Parkinson or
cancer.45 46 Through the use of this cellular model, recent
studies showed that J variant associates with decreased expres-
sion of specific genes related to inflammatory response, comple-
ment and apoptosis when compared with the haplogroup H.12
The functional analysis described herein included specific meta-
bolic measurements using an extracellular flux analyser as well
as specific aspects proposed to be related to OA, such as mito-
chondrial reactive oxygen species (ROS) production, oxidative
stress and apoptosis.7 44 47 The results obtained reveal that cells
harbouring the haplogroup J show a physiological behaviour
that seems to be protective against the development of OA.
This physiological behaviour includes a significantly lower
production of mitochondrial superoxide anion and peroxyni-
trite, as well as a higher ability to cope with oxidative stress. It
has been demonstrated that mitochondria-derived ROS and
nitrogen radicals lead to an upregulation of MMPs44 as well as
an overproduction of pro-inflammatory cytokines,48 cellular
damage or, in some cases, apoptosis. Interestingly, cybrids har-
bouring the haplogroup J show a significant lower rate of apop-
tosis under stress conditions, and a lower expression of the
pro-apoptotic gene BBC3, which induces apoptosis through
mitochondrial dysfunction.
From a metabolic point of view, haplogroups H and J have a
different behaviour too. H cybrids show higher mitochondrial
respiration rate and glycolytic capacity, which is reflected in an
increased ATP generation compared with cybrids carrying the
haplogroup J. The haplogroup H presents the highest levels of
conserved amino acids,9 which could determine its Oxidative
Phosphorylation System (OXPHOS) coupling efficiency and ATP
production41; however, this high efficiency would be accompan-
ied by an increased ROS generation and a higher oxygen con-
sumption, as demonstrated herein and proposed elsewhere.10 41
In recent years, several studies supported a key role of the
mitochondria in the pathogenesis of OA and the study of this
organelle in the context of this disease attracted much atten-
tion.2 49 50 The mechanisms underlying, at least in part, the
association described herein are related to different functional
consequences characteristic of specific mitochondrial
polymorphisms; thus, ROS production (both peroxynitrite and
superoxide anion), oxidative stress and apoptosis are downregu-
lated in cells harbouring mitochondrial polymorphisms charac-
teristic of the mtDNA haplogroup J.
Although a direct functional link between haplogroups and
cartilage biology has not been made in this study, a recent work
in conplastic mice (mice with constant nuclear background but
different mtDNA variants) shows that mtDNA haplotype pro-
foundly influences in health longevity through mitochondrial
proteostasis and ROS generation, insulin signalling, obesity, telo-
mere shortening or mitochondrial dysfunction.51 Because most
of these aspects are also involved in OA pathogenesis, a func-
tional link between mtDNA variation and cartilage biology
could really exist.
Despite only two studies were combined, the results of the
meta-analysis are consistent enough to support a real association
of haplogroup J with a lower risk of incident knee OA.
Furthermore, data from both cohorts were analysed in a similar
way, and effect size measures were adjusted for baseline
characteristics in order to minimise residual confounding. Both
OAI and CHECK are well-characterised cohorts, constructed
with rigorous methodology in which patients are evaluated by
objective methods in spaced visits. This should contribute to
minimise information biases and strengthen the conclusions of
this study.
In summary, the results of this work have a special clinical
relevance. On the one hand, they claim that polymorphisms of
the mtDNA haplogroup J alter metabolism and cell physiology
predisposing the cell to a less favourable environment to
develop incident OA, which allows the design of potential drugs
that emulate the physiological effects related to this haplogroup,
as well as the consideration of the mtDNA haplogroups as can-
didate diagnostic biomarkers in OA; among these therapeutic
strategies, potential drugs that modulate the activity of the mito-
chondrial respiratory chain in a similar way to that of the hap-
logroup J, or even the development of a cellular therapy using
cells with mitochondria harbouring the haplogroup J, could be
interesting. On the other hand, the results obtained permit to
select patients with OA not harbouring the haplogroup J (ie,
haplogroup H) as ideal candidates for clinical trials because they
are more likely to suffer a higher rate of incident knee OA.
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